RBC Reddit Mentions | ChartExchange

I used to have a more detailed DD on an old account which has since been deleted, but I wanted to post one again because I think this is a rare, generational wealth building opportunity, and it is my hope that this will interest some people here. Compass Pathways is a UK based biotech company that is working on a novel therapeutic for treatment resistant depression that will likely be more effective than SPRAVATO (the only current ketamine-based drug available for treatment resistant depression). Notable backers of the company include Peter Thiel who co-founded Paypal and Palantir and billionaire Christian Angermayer (Apeiron Investment Group). Their primary drug COMP360 is a synthetic, proprietary form of psilocybin that is currently in phase 3 clinical trials, with topline data expected in late June 2025. They also have separate trials ongoing for PTSD and Anorexia, but the June 2025 data will be from their TRD trial. The financials of the company are solid, and they have enough cash on hand to fund operations well into 2026.
I believe that there is a strong probability the trial data will be positive, and as is so common in biotech after positive phase 3 results, I think the stock will surge to $10, possibly more. And I am not the only one. Price targets don't mean a whole lot honestly, but a lot of analysts are similarly bullish on Compass. For instance, despite an initial trial delay last year, RBC Capital Markets see's long term value in the company and has [set a price target of $18](https://www.investing.com/news/company-news/trial-delays-eyed-for-compass-pathwaysrbc-still-sees-longterm-promise-on-stock-93CH-3696852). Similarly, Morgan Stanley has assigned Compass an “overweight” rating, with a price target of $17.
The price of the stock is down significantly from its all-time high but in the past month alone it has gone up by over 50%. A key reason I am so bullish on Compass Pathways is the more favourable regulatory environment in the US following the 2024 presidential election. Specifically, three individuals I think could be a game changer for psychedelics are FDA commissioner Dr. Marty Makary, HHS Secretary RFK Jr, and Veteran’s Affairs Secretary Doug Collins. Recently, [FDA Commissioner Marty Makary signaled his support for exploring the use of psychedelics to treat neuropsychiatric conditions, noting in an interview last Friday on NewsNation that the FDA will “take an expeditious and rapid review” of clinical data for psychedelic therapies in trials](https://www.biospace.com/fda/makary-backs-psychedelics-for-neuropsych-promises-speedy-review#:~:text=FDA%20Commissioner%20Marty%20Makary%20signaled,for%20psychedelic%20therapies%20in%20trials.).
VA Secretary Collins has pledged to press congress on taking action, and he spoke with Kennedy
about [how to navigate the regulatory and bureaucratic barriers to freeing up funds to support psychedelics access](https://www.marijuanamoment.net/trumps-veterans-secretary-had-eye-opening-psychedelics-talk-with-rfk-jr-and-he-plans-to-press-congress-to-act/).
Tl;dr: I believe Compass Pathways will be the first company to commercialize a psilocybin based therapeutic for treatment resistant depression. I believe in the short term, phase 3 results will be successful propelling the stock to $10 or more, and in the long term they will obtain FDA approval which could see the stock rise to $30+.
My position: Opportunities like this in my opinion are rare. 2000 shares and 80 contracts. 50 $7.5c exp July 18th 2025 and 30 $7.50c exp Aug 15th 2025.

document.getElementById("tys1GF").onerror = function(){this.style.display='none';}; .dark-mode .NgGxbS{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .NgGxbS{ color: #333333; background-color: white; border: 2px solid #333333; }RBCRBC Bearings Incorporatedstock NYSE

RBC
RBC Bearings Incorporated
stock NYSE